Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
British Journal of Haematology
|
March 12, 2002
Veno-occlusive disease after an anti-CD33 therapy (gemtuzumab ozogamicin)
J N Bastie, F Suzan, I Garcia, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
October 1, 1996
Interleukin-2 in outpatients with renal cell carcinoma: SCAPP1 trial
J M Tourani, P Grise, V Lucas, et al.
British Journal of Cancer
|
November 27, 2001
High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study
P H Cottu, J M Extra, M Espie, et al.
Bulletin Du Cancer
|
April 1, 1997
[Subcutaneous administration of interleukin-2 in ambulatory treatment of patients with metastatic renal cancer. Three-year results of the SCAPP I program]
J M Tourani, C Jaillon-Abraham, V Lucas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 29, 2009
A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group
I Ray-Coquard, S Dussart, C Goillot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 1996
Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial
J M Tourani, V Lucas, D Mayeur, et al.
ESMO Open
|
June 10, 2025
Financial toxicity and socioeconomic impact of cancer in Europe
J Vancoppenolle, N Franzen, L Azarang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 17, 1998
Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group
J M Tourani, C Pfister, J F Berdah, et al.
Thrombosis Research
|
June 5, 2023
Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool
J Goedegebuur, D Abbel, S Accassat, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
British Journal of Haematology
|
March 12, 2002
Veno-occlusive disease after an anti-CD33 therapy (gemtuzumab ozogamicin)
J N Bastie, F Suzan, I Garcia, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
October 1, 1996
Interleukin-2 in outpatients with renal cell carcinoma: SCAPP1 trial
J M Tourani, P Grise, V Lucas, et al.
British Journal of Cancer
|
November 27, 2001
High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study
P H Cottu, J M Extra, M Espie, et al.
Bulletin Du Cancer
|
April 1, 1997
[Subcutaneous administration of interleukin-2 in ambulatory treatment of patients with metastatic renal cancer. Three-year results of the SCAPP I program]
J M Tourani, C Jaillon-Abraham, V Lucas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 29, 2009
A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group
I Ray-Coquard, S Dussart, C Goillot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 1996
Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial
J M Tourani, V Lucas, D Mayeur, et al.
ESMO Open
|
June 10, 2025
Financial toxicity and socioeconomic impact of cancer in Europe
J Vancoppenolle, N Franzen, L Azarang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 17, 1998
Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group
J M Tourani, C Pfister, J F Berdah, et al.
Thrombosis Research
|
June 5, 2023
Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool
J Goedegebuur, D Abbel, S Accassat, et al.
Page
of 2